NASDAQ:CLVR - Nasdaq - CA1867602031 - Common Stock - Currency: USD
3
+0.89 (+42.18%)
The current stock price of CLVR is 3 USD. In the past month the price decreased by -26.74%. In the past year, price decreased by -60.1%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 56.36 | 734.92B | ||
JNJ | JOHNSON & JOHNSON | 15.17 | 366.71B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 18.57 | 304.42B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.44 | 237.03B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 15.87 | 216.57B | ||
MRK | MERCK & CO. INC. | 10.15 | 198.62B | ||
PFE | PFIZER INC | 7.54 | 137.53B | ||
SNY | SANOFI-ADR | 10.49 | 116.45B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.31 | 94.33B | ||
GSK | GSK PLC-SPON ADR | 8.54 | 78.19B | ||
ZTS | ZOETIS INC | 25.94 | 69.53B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 62.92 | 47.17B |
Clever Leaves Holdings Inc is a CO-based company operating in Pharmaceuticals industry. The company employs 400 full-time employees The company went IPO on 2020-12-18. Clever Leaves Holdings Inc. is a multinational operator and licensed producer of pharmaceutical-grade cannabinoids. The firm's segments include Cannabinoid and Non-Cannabinoid. The Cannabinoid segment is comprised of cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products. The Non-Cannabinoid operating segment is comprised of the brands and manufacturing assets acquired as part of its acquisition of Herbal Brands. The Non-Cannabinoid segment is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing wellness products and nutraceuticals, excluding cannabinoid products. Its customers for the Herbal Brands products include specialty and health retailers, mass retailers and specialty and health stores in the United States. The company offers product portfolio in two categories: nutraceuticals and cannabinoids. The nutraceutical products consist of a variety of beverage and powder products.
CLEVER LEAVES HOLDINGS INC
Bodega 19-B Parque Industrial Tibitoc Ph, Tocancipa - Cundinamarca
Boca Raton FLORIDA 10017 CO
CEO: Kyle Detwiler
Employees: 400
Phone: 16468804382.0
The current stock price of CLVR is 3 USD. The price increased by 42.18% in the last trading session.
The exchange symbol of CLEVER LEAVES HOLDINGS INC is CLVR and it is listed on the Nasdaq exchange.
CLVR stock is listed on the Nasdaq exchange.
6 analysts have analysed CLVR and the average price target is 24.48 USD. This implies a price increase of 716% is expected in the next year compared to the current price of 3. Check the CLEVER LEAVES HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CLEVER LEAVES HOLDINGS INC (CLVR) has a market capitalization of 5.25M USD. This makes CLVR a Nano Cap stock.
CLEVER LEAVES HOLDINGS INC (CLVR) currently has 400 employees.
CLEVER LEAVES HOLDINGS INC (CLVR) has a resistance level at 3.11. Check the full technical report for a detailed analysis of CLVR support and resistance levels.
The Revenue of CLEVER LEAVES HOLDINGS INC (CLVR) is expected to grow by 50% in the next year. Check the estimates tab for more information on the CLVR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CLVR does not pay a dividend.
CLEVER LEAVES HOLDINGS INC (CLVR) will report earnings on 2024-08-12, after the market close.
CLEVER LEAVES HOLDINGS INC (CLVR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.4).
The outstanding short interest for CLEVER LEAVES HOLDINGS INC (CLVR) is 0.54% of its float. Check the ownership tab for more information on the CLVR short interest.
ChartMill assigns a fundamental rating of 2 / 10 to CLVR. CLVR has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months CLVR reported a non-GAAP Earnings per Share(EPS) of -11.4. The EPS increased by 78.15% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -57.31% | ||
ROE | -73.94% | ||
Debt/Equity | 0.03 |
ChartMill assigns a Buy % Consensus number of 43% to CLVR. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 29.03% and a revenue growth 50% for CLVR